Premium
Clinical trials update from the European Society of Cardiology heart failure meeting: TNT subgroup analysis, darbepoetin alfa, FERRIC‐HF and KW‐3902
Author(s) -
Coletta Alison P.,
Tin Lwin,
Loh P. Huan,
Clark Andrew L.,
Cleland John G.F.
Publication year - 2006
Publication title -
european journal of heart failure
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.149
H-Index - 133
eISSN - 1879-0844
pISSN - 1388-9842
DOI - 10.1016/j.ejheart.2006.07.003
Subject(s) - medicine , heart failure , cardiology , darbepoetin alfa , atorvastatin , placebo , diuretic , anemia , alternative medicine , pathology
This article provides information and a commentary on trials relevant to the pathophysiology, prevention and treatment of heart failure, presented at the European Society of Cardiology heart failure meeting held in June 2006. All reports should be considered as preliminary data, as analyses may change in the final publication. In a sub‐group analysis of the TNT study, intensive treatment with high‐dose atorvastatin significantly reduced hospitalisations for heart failure in patients with stable coronary heart disease, compared with low‐dose atorvastatin; this benefit was most evident in patients with a history of heart failure at baseline. In a combined analysis of two studies of darbepoetin alfa, which included 475 patients, treatment increased and maintained haemoglobin levels and produced non‐significant improvements in symptoms and morbidity in anaemic heart failure patients compared to placebo. In the FERRIC‐HF study ( n =35), intravenous iron sucrose therapy improved exercise capacity and symptom status in iron‐deficient heart failure patients. In a combined analysis of two studies ( n =186), the adenosine A 1 receptor antagonist KW‐3902 showed diuretic properties and appeared to enhance response to loop diuretics in heart failure patients hospitalised with fluid overload.